What is Tesamorelin?
Tesamorelin is a synthetic GHRH analog that is currently FDA-approved (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is one of the few peptides in this space with full FDA approval for a therapeutic indication, which provides a stronger evidence base than most other peptides discussed for body composition.
What Tesamorelin Is Investigated For
Tesamorelin is investigated and FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, and the strongest evidence — a full Phase 3 program published by Falutz and colleagues — established a 15.2% visceral fat reduction at the 26-week primary endpoint in the first pivotal trial and −10.9% at six months in the second, deepening to roughly 18% in the patients who stayed on drug through 52 weeks. It is the only GHRH analog currently holding FDA approval, which places it in a different regulatory and evidence tier from CJC-1295 or modified GRF(1-29). Off-label interest centers on adult body composition, cognitive function (with a small Baker et al. mild cognitive impairment trial), and non-HIV NAFLD. The honest caveats are important: the approved evidence base is specific to HIV-lipodystrophy, dedicated RCTs of tesamorelin in healthy aging adults for longevity or body-composition goals do not exist, visceral fat regresses when treatment stops (the benefit is chronic-treatment-dependent, not one-time remodeling), and tesamorelin is named on WADA's Prohibited List (S2.2.4) regardless of its FDA-approved status. Glucose and HbA1c monitoring is built into the label because GH elevation worsens glycemic control.
History & Discovery
Tesamorelin was developed by Theratechnologies, a Montreal-based biopharmaceutical company, and represents an unusual case in the peptide landscape: a GHRH analog that successfully completed the full regulatory pathway and reached FDA approval. The compound is a synthetic analog of human growth hormone-releasing hormone, GHRH(1-44), with a single N-terminal modification — a trans-3-hexenoyl group attached to the tyrosine at position 1 — that dramatically reduces proteolytic degradation and extends in vivo activity compared to native GHRH. The underlying GHRH structure was characterized at the Salk Institute in the 1980s by Roger Guillemin's group; Theratechnologies' contribution was the stabilizing modification and the completion of the clinical development program. The development program targeted HIV-associated lipodystrophy, a treatment-related condition in which antiretroviral therapy causes excess visceral fat accumulation along with peripheral lipoatrophy. The Phase III program, published by Falutz, Mamputu, and colleagues between 2007 and 2010, demonstrated significant visceral adipose tissue reduction measured by CT scan, with concurrent improvements in lipid profile and adiponectin. The FDA approved tesamorelin as Egrifta in November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and Health Canada approval followed. Tesamorelin remains the only GHRH analog with current FDA approval — sermorelin (the shorter GHRH(1-29) fragment) had prior approvals as Geref, but the products were discontinued in 2008 and the approvals withdrawn at the sponsor's request in 2009, and all other GHRH analogs discussed in wellness contexts (CJC-1295, modified GRF 1-29) remain unapproved investigational compounds. More recently, Theratechnologies reformulated the product as Egrifta SV (single-vial, the F1 formulation retaining the 2 mg daily dose) and Egrifta WR (F8 formulation approved by the FDA on March 25, 2025, with commercial launch on September 5, 2025) — the WR variant uses weekly rather than daily reconstitution and delivers a lower 1.28 mg daily dose (0.16 mL from an 11.6 mg vial supplying a 7-day reconstituted course), bioequivalent to F1 with about half the injection volume. In September 2025 Theratechnologies was acquired by Future Pak / CB Biotechnology following a definitive agreement announced in July 2025, with commercialization of the Egrifta franchise now passing to the new owner. The compound has also been studied off-label for cognitive endpoints (Baker and colleagues, mild cognitive impairment) and for non-HIV NAFLD.
How It Works
Tesamorelin works the same way as your body's natural growth hormone-releasing hormone, but with modifications that make it more potent and longer-lasting. It tells your pituitary gland to release more growth hormone, which in turn helps reduce visceral (deep belly) fat.
Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that enhances receptor binding affinity and resistance to enzymatic degradation. It binds to pituitary GHRH receptors, stimulating GH synthesis and secretion. Clinical trials have demonstrated significant reductions in visceral adipose tissue (VAT) as measured by CT scan, along with improvements in trunk fat and lipid profiles.
Evidence Snapshot
Human Clinical Evidence
Very strong. Multiple Phase III randomized controlled trials. FDA-approved based on rigorous clinical evidence.
Animal / Preclinical
Strong. Comprehensive preclinical development program.
Mechanistic Rationale
Very strong. Well-characterized GHRH receptor agonism.
Research Gaps & Open Questions
What the current literature has not yet settled about Tesamorelin:
- 01Long-term (>2 year) safety data outside the HIV-lipodystrophy population is limited; the pivotal program's extension data extends to roughly 52 weeks, and chronic multi-year use in non-HIV populations is less well-characterized than the approved indication suggests on first reading. A mandated 10-year post-marketing cohort study is tracking malignancy, type 2 diabetes, retinopathy, and major adverse cardiovascular events in HIV-lipodystrophy patients on tesamorelin — this is the primary source of emerging chronic-use safety data but has not yet fully reported.
- 02Efficacy and safety of tesamorelin specifically in healthy aging adults pursuing body-composition or longevity goals — the dominant off-label use case — has not been tested in dedicated RCTs. The cognitive-impairment trial by Baker and colleagues is an exception but remains small.
- 03Tesamorelin's effect on cardiovascular endpoints (MACE, heart failure, arrhythmia) over years of continuous use has not been directly characterized in a dedicated endpoint trial; available data is limited to metabolic-marker improvements.
- 04Whether tesamorelin's favorable outcomes in NAFLD translate to hard liver endpoints (fibrosis progression, hepatocellular carcinoma incidence) in populations without HIV coinfection has not been established.
- 05Comparative effectiveness data against newer GHRH analogs and against non-GHRH weight-management therapies (particularly GLP-1 receptor agonists) for visceral fat reduction in non-HIV populations is sparse.
- 06Durability of benefit after discontinuation has been characterized in HIV-lipodystrophy but not in other off-label populations; the regression-after-discontinuation finding is meaningful for patient counseling about long-term commitment.
Forms & Administration
Tesamorelin is administered via subcutaneous injection. As an FDA-approved medication, it has specific prescribing information and dosing guidelines available. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The FDA-approved adult dose of tesamorelin for HIV-associated lipodystrophy is 2 mg subcutaneously once daily using Egrifta SV (F1 formulation) — the dose established across the Phase III program. Egrifta WR (F8 formulation, FDA-approved March 25, 2025; commercial September 5, 2025) is bioequivalent but delivers a lower 1.28 mg daily dose (0.16 mL from an 11.6 mg vial reconstituted weekly), reflecting the reformulation rather than a reduced clinical target. Off-label protocols in the wellness and longevity space largely mirror the daily dose of whichever formulation is prescribed. Dose reduction below labeled levels is not typically discussed because sub-therapeutic dosing is unlikely to reproduce the clinical-trial body-composition effects.
Frequency
Tesamorelin is dosed once daily via subcutaneous injection. Its short pharmacokinetic half-life (plasma clearance within hours) is balanced by its persistent ability to stimulate pulsatile GH release; daily dosing produces sustained IGF-1 elevation. The labeled administration time is consistent across doses, with morning or evening administration both acceptable. Unlike shorter-acting GHRH peptides that are sometimes dosed multiple times per day, tesamorelin's potency and stability make once-daily the standard.
Timing Considerations
Time of day
Evening or bedtime injection is the standard protocol, matching both the natural nocturnal GH pulse and the regimen used in the HIV-lipodystrophy approval trials.
Relative to meals
Fasted is preferable for maximum GH response — at least 30 minutes before food and a few hours after a meal — though tesamorelin's GHRH-receptor mechanism is less meal-sensitive than ghrelin-mimetics like ipamorelin or GHRP-6.
Relative to exercise
Not tied to training.
Cycle Length
The approved indication supports continuous daily use. Theratechnologies' long-term extension data (published by Falutz and colleagues) support continued use beyond 26 weeks with sustained visceral-fat reduction and a reasonable safety profile in the HIV-lipodystrophy population. The FDA label does not specify a maximum duration. In off-label wellness use, practitioners sometimes cycle tesamorelin in 3–6 month blocks with breaks, though this pattern is a generic GH-secretagogue convention rather than a tesamorelin-specific evidence-based practice. Published efficacy is tied to continued dosing: the visceral-fat reduction regresses when treatment is stopped.
Protocol Notes
Tesamorelin is supplied as a lyophilized powder in vials, reconstituted with supplied sterile water for injection per the product labeling. Egrifta SV (F1) is reconstituted daily; Egrifta WR (F8, approved March 2025) is reconstituted once and the reconstituted solution is drawn from across a 7-day course, reducing the daily handling burden and cutting injection volume by roughly half. Subcutaneous injection into the abdomen is the standard route for both formulations, with site rotation between abdominal quadrants to reduce injection-site reaction and avoid localized lipoatrophy or lipohypertrophy — particularly relevant given the lipodystrophy patient population. Injection timing is not meal-dependent in the same way ghrelin-receptor agonists are, because tesamorelin acts at the GHRH receptor rather than the ghrelin receptor, and the GH-releasing effect is not blunted by recent food intake to the same degree. Monitoring of IGF-1 levels, glucose, and HbA1c is standard during treatment. The approved product comes with formal prescribing information; this site is not a substitute for that document.
Tesamorelin is FDA-approved only for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. All other uses — general wellness, longevity, non-HIV body composition, cognitive enhancement — are off-label. Off-label use should be undertaken only under qualified clinician supervision with appropriate monitoring.
Timeline of Effects
Onset
Serum IGF-1 elevation is measurable within days of starting daily dosing, with a substantial rise typically evident by the end of the first week. Subjective effects — improved sleep quality, modest early recovery benefits — often appear in the first 2–4 weeks. The indication-defining outcome, visceral adipose tissue reduction, is not measurable until weeks of consistent dosing; the Phase III trials reported statistically significant VAT reduction at the 26-week primary endpoint, with effect sizes building progressively through the dosing period.
Peak Effect
Visceral fat reduction in the Phase III program reached 15.2% at the 26-week primary endpoint in the first pivotal trial (−10.9% at six months in the second), then deepened to roughly 18% in patients who continued daily dosing through 52 weeks — the 18% figure belongs to the one-year mark, not the six-month one. IGF-1 elevation reaches a near-plateau within the first month and is sustained as long as daily dosing continues. Subjective body-composition, skin-quality, and sleep benefits reported in off-label wellness use most commonly plateau around 3–6 months, which aligns with the trial trajectory.
After Discontinuation
Because tesamorelin does not suppress endogenous GHRH — it augments the signal rather than replacing pituitary function — endogenous pulsatile GH secretion returns to baseline within days to weeks of discontinuation. IGF-1 drifts back to pre-treatment levels over 2–4 weeks. Crucially, the visceral-fat reduction achieved during treatment is not durable: the Phase III program demonstrated that patients who stopped tesamorelin after 26 weeks regained visceral fat over the subsequent months, while those who continued dosing maintained or further reduced VAT. This is a defining feature of the therapy — the effect is treatment-dependent, not a one-time remodeling.
Monitoring & Measurement
Bloodwork & Labs
- •IGF-1 (serum) — trials measured +81% at 26 weeks on the 2 mg dose and +117% at 20 weeks on the 1 mg dose; no cited trial reports a week-12 figure
- •Fasting glucose and HbA1c — tesamorelin trials showed modest fasting-glucose rises; worth early checks in anyone insulin-resistant at baseline
- •Lipid panel — visceral-fat reduction typically drives triglyceride drops
- •ALT and AST — VAT and hepatic fat correlate, so liver enzymes are a relevant adjacent marker
Functional & Performance Tests
- •Waist circumference — the simple, reliable visceral-fat proxy
- •DEXA scan with VAT segment — the closest at-home gold standard
- •Abdominal MRI or MRI-PDFF for NAFLD-focused users with access — the trial gold standard for both VAT and liver fat
When to Test
Baseline, 12 weeks, and 26 weeks — the 26-week mark mirrors the approval trial endpoint.
Interpretation & Notes
Tesamorelin's flagship outcome is a 15.2% visceral adipose tissue reduction at 26 weeks in the first pivotal trial, reaching roughly 18% after 52 weeks of continuous dosing — the 18% figure belongs to the one-year mark, not the six-month one. Abdominal MRI is the clinical gold standard for VAT measurement, but DEXA with VAT estimation and tape-measured waist circumference are reasonable proxies for most users. The pivotal trials measured IGF-1 at their own endpoints rather than at week 12: it rose 81% at 26 weeks on the 2 mg lipodystrophy dose and 117% at 20 weeks on the 1 mg dose used in the cognition trial. No cited trial reports a week-12 value, so treat an earlier draw as a directional adherence check rather than a benchmark — if IGF-1 has not moved at all at a therapeutic dose, investigate adherence and source quality before assuming non-response. Unlike ipamorelin and CJC-1295, tesamorelin has robust RCT data behind it, so the response distribution is well-characterized; deviations from expected trajectory are more interpretable. Panels are direct-to-consumer; imaging typically requires a clinician order.
Common Questions
Is Tesamorelin FDA-approved?
Yes. Tesamorelin (Egrifta) is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Off-label use for other purposes should be discussed with a clinician.
How is it different from other GH peptides?
Tesamorelin has the strongest regulatory evidence base of any GHRH analog. It has undergone rigorous Phase III clinical trials and FDA review.
Who Tesamorelin Is NOT For
- •Active malignancy — the FDA label explicitly contraindicates tesamorelin in patients with active malignancy, because sustained GH and IGF-1 elevation may accelerate proliferation of existing tumors. Patients with a prior history of cancer require careful individual evaluation; the label advises against initiating treatment in patients with active disease.
- •Disrupted hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma — tesamorelin requires an intact somatotroph axis to be pharmacologically useful, and its use is contraindicated in patients without one.
- •Pregnancy — tesamorelin is contraindicated in pregnancy per the approved label; the GH/IGF-1 axis changes substantially during pregnancy and the pharmacologic effects have not been characterized in reproductive-toxicology frameworks adequate to support use.
- •Known hypersensitivity to tesamorelin or mannitol (a formulation excipient) — serious hypersensitivity reactions including anaphylaxis have been reported.
- •Diabetes or impaired glucose tolerance — tesamorelin is not absolutely contraindicated in diabetes, but it can worsen glycemic control and the approved label requires glucose and HbA1c monitoring. In patients with poorly controlled diabetes, the risk-benefit calculation frequently argues against use.
- •Pediatric use — tesamorelin is not approved for use in pediatric patients, and long-bone growth considerations would require specialist oversight if considered.
Drug & Supplement Interactions
Tesamorelin has a more developed drug-interaction profile than most peptides in this space because of its FDA approval, though the human dataset remains modest. The prescribing information and published literature describe several meaningful interactions. Glucose-regulating medications — insulin, sulfonylureas, GLP-1 receptor agonists — interact with GH's counter-regulatory effect on glucose. Tesamorelin-treated patients frequently require dose adjustment of antidiabetic agents as IGF-1 rises and insulin sensitivity shifts; glucose and HbA1c monitoring is built into the approved prescribing information for exactly this reason. Corticosteroids (prednisone, dexamethasone) blunt GH secretion at the pituitary level and can attenuate tesamorelin's clinical effect; in the HIV-lipodystrophy population, concurrent corticosteroid use is a recognized consideration. In the HIV-treatment context, CYP3A4-metabolized drugs warrant attention: GH elevation can alter hepatic enzyme activity, and several antiretroviral agents are CYP3A4 substrates. Thyroid hormone status matters — hypothyroidism blunts GH response, and uncorrected thyroid dysfunction should be addressed first. Estrogens modulate GH/IGF-1 coupling, with oral estrogens in particular reducing hepatic IGF-1 generation, which affects interpretation of monitoring labs. Somatostatin analogs (octreotide, lanreotide) directly oppose GHRH signaling and will pharmacologically antagonize tesamorelin. Patients on any regular medication should discuss tesamorelin with their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • FDA-approved only for HIV lipodystrophy
- • Contraindicated in pregnancy
- • Monitor IGF-1 levels
- • Discontinue if hypersensitivity occurs
What We Don't Know
Long-term effects beyond the studied HIV lipodystrophy population are less characterized for off-label applications.
Legal Status
United States
Tesamorelin is FDA-approved (brand names Egrifta, Egrifta SV, Egrifta WR) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, approved November 2010. It is the only GHRH analog with current FDA approval — sermorelin's Geref products were discontinued in 2008 and their approvals withdrawn at the sponsor's request in 2009, and all other GHRH analogs discussed in wellness contexts (CJC-1295, modified GRF 1-29) remain unapproved. Tesamorelin is a prescription drug distributed through specialty pharmacy channels. All non-HIV uses are off-label; off-label prescribing is legal under physician judgment in the US but is not evidence-based in the same way the approved indication is, and it is not covered by the approved labeling's safety monitoring framework.
International
Tesamorelin is approved by Health Canada under the same HIV-lipodystrophy indication. The European Medicines Agency initially authorized tesamorelin (as Egrifta) in 2014 but the marketing authorization was subsequently withdrawn by the sponsor. Australian and other national regulatory treatments vary. Outside approved indications, regulatory treatment mirrors other GHRH analogs in the respective jurisdictions.
Sports & Competition
Tesamorelin is explicitly prohibited under WADA's S2.2.4 (growth hormone releasing factors), which names tesamorelin alongside sermorelin and CJC-1295 as GHRH analogues — prohibited at all times, both in and out of competition. The FDA-approved HIV-lipodystrophy indication may qualify for a Therapeutic Use Exemption (TUE) under WADA code for an athlete with a medically documented need, but this is a case-by-case TUE process, not a blanket exemption. Off-label use for performance or body composition by an athlete subject to WADA code would be a prohibited substance violation. Athletes should not assume the FDA-approved status provides any automatic doping protection.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Tesamorelin is the same thing as CJC-1295 because both are GHRH analogs.
Reality
They are different molecules with different pharmacology and, crucially, different regulatory status. Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl modification, dosed daily, FDA-approved for HIV-lipodystrophy with a full Phase III evidence base. CJC-1295 has different amino acid substitutions and, in its DAC form, a maleimide linker that covalently binds serum albumin for week-long half-life; it was never FDA-approved and its sponsor's clinical program was abandoned after a safety signal. Shared class does not equal shared evidence.
Myth
Because tesamorelin is FDA-approved, it is safe and appropriate for anti-aging and longevity use.
Reality
FDA approval applies specifically to reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Off-label anti-aging and longevity use is legal under physician judgment but is not supported by the approval evidence base, is not covered by the approved safety monitoring framework, and involves the same theoretical GH/IGF-1 concerns — particularly around cancer risk — that attach to other GH secretagogues. The approved indication is narrow and the off-label leap is substantial.
Myth
Tesamorelin 'reprograms' your metabolism so the visceral fat loss is permanent.
Reality
The Phase III extension data shows visceral fat regresses when treatment stops — patients who discontinued tesamorelin regained VAT over subsequent months, while those who continued dosing maintained the reduction. Tesamorelin is a chronic treatment, not a one-time remodeling intervention. Patient counseling that implies 'do a cycle and you're done' misrepresents what the evidence actually supports.
Myth
Tesamorelin is not on the WADA list because it is FDA-approved.
Reality
Tesamorelin is named in WADA S2.2.4 alongside other GHRH analogues, regardless of its FDA-approved status for HIV-lipodystrophy. An athlete with documented HIV-associated lipodystrophy might pursue a Therapeutic Use Exemption, but that is a case-by-case medical process, not an automatic exemption based on the drug being approved. Off-label sports use by any athlete subject to WADA code would be a prohibited substance violation.
Myth
Tesamorelin is safe in pregnancy because it just boosts natural GHRH.
Reality
Tesamorelin is contraindicated in pregnancy per the approved FDA label. 'Augments a natural pathway' is not a safety argument in pregnancy — the endocrine changes of pregnancy are complex, pharmacologic GH/IGF-1 elevation has not been characterized in reproductive-toxicology studies adequate to support use, and the contraindication reflects the absence of safety evidence rather than a formalistic caution.
Published Research
32 studiesDiffering Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists (Clin Infect Dis, 2026)
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
The first meta-analysis to pool the randomized tesamorelin evidence — five RCTs, risk of bias by RoB 2.0 and certainty by GRADE — and it quantifies the class claim: visceral adipose tissue −27.7 cm² (95% CI −38.4 to −17.1), hepatic fat −4.28%, trunk fat −1.18 kg and lean mass +1.42 kg, with no significant change in subcutaneous adipose tissue, BMI or CD4 count. The selectivity for visceral over subcutaneous depots survives pooling, which is the single most important thing to know about the drug.
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease
Tesamorelin
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
The definitive NAFLD trial: 61 people with HIV and a hepatic fat fraction of 5% or more, randomized to 2 mg daily or placebo for 12 months with a 6-month open-label tail. Hepatic fat fell 37% in relative terms (absolute effect −4.1%), and 35% of the tesamorelin arm versus 4% of placebo finished below the 5% steatosis threshold, with no separation in fasting glucose or HbA1c. Every statement on this page about tesamorelin and liver fat traces to this trial.
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
The dedicated glycemic-safety study, and the reason diabetes is a monitoring requirement on the label rather than a contraindication: 53 patients with type 2 diabetes randomized to placebo, 1 mg or 2 mg tesamorelin for 12 weeks, with no significant between-group difference in insulin response to oral glucose, fasting glucose, HbA1c or the need to modify diabetes medications, and no discontinuations for loss of glycemic control. Total and non-HDL cholesterol fell in the 2 mg arm.
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
The trial that first put liver fat alongside visceral fat as a co-primary endpoint: 50 antiretroviral-treated adults at Massachusetts General Hospital on 2 mg daily for six months, with a −42 cm² treatment effect on VAT and a −2.9% net reduction in hepatic lipid-to-water percentage. It also produced the clearest glucose signal in the literature — fasting glucose 7 mg/dL above placebo at two weeks, no longer significant by six months — which is why glucose monitoring is front-loaded rather than occasional.
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH
Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial
The only 12-month randomized trial of tesamorelin in a non-HIV population: 60 abdominally obese adults with reduced GH secretion on 2 mg daily or placebo. Visceral fat fell by a −35 cm² treatment effect with no effect on subcutaneous fat, and carotid intima-media thickness (−0.04 mm), CRP and triglycerides all improved with no change in fasting glucose, 2-hour glucose or HbA1c. It is the closest thing to evidence for the off-label body-composition use case — and it is one trial of 60 people.
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
The cognition trial the entire off-label nootropic argument leans on: 152 adults aged 55–87, 66 of them with mild cognitive impairment, self-injecting 1 mg tesamorelin or placebo 30 minutes before bedtime for 20 weeks at the University of Washington. Intent-to-treat analysis found a favorable effect on cognition (P=.03) driven by executive function (P=.005), with IGF-1 up 117% and body fat down 7.4%. Note the dose — 1 mg, half the lipodystrophy dose — and that the effect was comparable in healthy older adults and MCI.
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
Spotlight on tesamorelin in HIV-associated lipodystrophy
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy
Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
The second pivotal trial, and the one that defined the shape of the therapy: 404 patients randomized 2:1 for six months and then re-randomized, with VAT down 10.9% (−21 cm²) versus 0.6% on placebo at six months and roughly 18% in those who stayed on drug through twelve. Patients switched from tesamorelin to placebo rapidly lost the reduction — that withdrawal arm is the origin of the treatment-dependent framing used throughout this page.
Tesamorelin, a human growth hormone releasing factor analogue
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
The 26-week safety extension of the pivotal program, re-randomizing the original 410 patients into continue-tesamorelin (n=154), switch-to-placebo (n=50) and placebo-to-tesamorelin (n=111) arms. VAT reduction held at −18% across 52 weeks with triglycerides down 51 mg/dL and no clinically meaningful glucose drift, while VAT reaccumulated in everyone who stopped. Still the longest controlled dataset on the compound.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
The first pivotal Phase 3 trial, and the paper that turned tesamorelin into a drug: 412 HIV patients with abdominal fat accumulation randomized to 2 mg daily or placebo for 26 weeks, with CT-measured visceral adipose tissue falling 15.2% on tesamorelin while rising 5.0% on placebo. Triglycerides dropped 50 mg/dL, IGF-1 rose 81%, and no significant difference appeared in glycemic measures — the combination of visceral selectivity and glucose neutrality the FDA submission rested on.
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor
Popular Stacks Including Tesamorelin
Tesamorelin + Ipamorelin (FDA-Backed GHRH Analog + Selective Ghrelin-Mimetic)
A growth hormone secretagogue stack that pairs the only FDA-approved GHRH analog (tesamorelin) with the cleanest ghrelin-receptor trigger (ipamorelin). Delivers the same GHRH + ghrelin dual-pathway synergy as CJC-1295 + ipamorelin, with tesamorelin's Phase III evidence base standing in for the compounded GHRH leg.
Retatrutide + Tesamorelin
A gray-market pairing of Lilly's unapproved triple agonist retatrutide (or, more often, tirzepatide) with tesamorelin, the FDA-approved GHRH analog for HIV-associated belly fat. The pitch is extra visceral-fat loss and protected muscle. No trial has tested it. Growth hormone works against the incretin's blood-sugar benefit, GLP-1-class drugs already cut visceral fat on their own, and 'tesamorelin preserves lean mass on a GLP-1' is untested.
Quick Facts
- Class
- GHRH Analog
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 32PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.